For instance the company's lead program targets two forms of a protein receptor called IL2 as well as surface proteins found on certain T cells. The therapy is meant to work only when all targets are bound at the same time in theory limiting its action only to those cells. The approach overlaps in some respects with research on drugs known as bispecific antibodies which are meant to bring two different types of cells together